EEG/MECG/EMG Evaluating the Severity of Aortic Stenosis, Heart Failure and Ischemic Stroke Through an Artificial Intelligenceassisted System.

Study Overview
=================
Brief Summary
-----------------
The specific objectives and methods of this project are: (1) To test the feasibility and accuracy of integrating EEG, MECG and EMG for detecting the severity of diseases such as aortic stenosis, heart failure and ischemic stroke. (2) Improve the accuracy of this multi-channel brain-heart-muscle device by using an artificial intelligence auxiliary system. (3) Provide tailor-made interdisciplinary treatment strategies for patients with different disease states.

Official Title
-----------------
Assessment of Brain-heart-muscle Axis Using EEG/MECG/EMG Combo Machine for Evaluating the Severity of Aortic Stenosis, Heart Failure and Ischemic Stroke Through an Artificial Intelligenceassisted System.

Conditions
-----------------
CVD

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Age≥20 year-old Healthy subjects or patients with A. Metabolic syndrome (MetS) ；B. HF with reduced ejection fractions (HFrEF, defined by left ventricular ejection fraction≤40%) and current or previous symptoms of HF；C. Severe aortic stenosis (defined aortic valve area < 1.0 cm2 or mean pressure gradient ≥ 40 mmHg), preparing to receive transcatheter aortic valve replacement ；D. Acute ischemic stroke and admitted to stroke intensive care unit (ICU), within 24 hours after onset The criteria of MetS includes: Abdominal obesity: waist circumference (for Asians) ≥ 90 cm in men and ≥ 80 cm in women; Hyperglycemia: serum fasting glucose level ≥ 100 mg/dl, or receiving drug treatment for elevated blood sugar; Reduced high-density lipoprotein cholesterol (HDL-C): serum HDL-C < 40 mg/dl in men and < 50 mg/dl in women or on cholesterol drug treatment; Elevated triglycerides: serum triglyceride ≥ 150 mg/dl or on drug treatment of hypertriglyceridemia; Hypertension: systolic blood pressure ≥ 130 mmHg, diastolic blood pressure ≥ 85 mmHg, or on antihypertensive drug treatment. Exclusion criteria: Under treatment for malignancy Currently receiving immunosuppressants Modified Rankin Scale (mRS) ≥2 prior to the stroke Symptomatic HF in patients with acute ischemic stroke Unable to perform neurocognitive function test Unable to evaluate the physical activity using questionnaire or 6-minute walk test Unable to cooperate with examinations using 3E combo machine.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy subjects group<br>150 healthy subjects | |
| Metabolic syndrome group<br>100 patients with clinical diagnosis of metabolic syndrome. | |
| Heart failure group<br>100 patients with clinical diagnosis of heart failure. | |
| Heart failure with metabolic syndrome group<br>100 patients with clinical diagnosis of heart failure with metabolic syndrome. | |
| Severe aortic valve stenosis group<br>100 patients with clinical diagnosis of severe aortic valve stenosis. | |
| Ischemic stroke group<br>200 patients with clinical diagnosis of ischemic stroke. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite cardiovascular outcome | Composite endpoint: Major adverse cardiac events (MACE): myocardial infarction, stroke, hospitalization for heart failure, or cardiovascular death) | up to 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
heart failure, aortic stenosis, ischemic stroke